KYKeiji Yoshioka

Keiji Yoshioka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Keiji Yoshioka has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Non-clinical safety of novel cross-linked chondroitin sulfate (SI-449) as an anti-adhesion barrier for abdominal and pelvic surgeries

    by Ayako Shiraki, Shino Ito, Dai Muramatsu, Tomoki Sasaki, Akira Otsuka, Tomomi Miyahara, Katsuya Takahashi, Keiji Yoshioka, Miki Suehiro

    Postoperative adhesions result from abnormal tissue repair and most frequently occur in patients following abdominal and pelvic surgeries. Prevention of adhesion formation, including the use of anti-adhesion barriers during surgery, is considered the most effective clinical strategy for postoperative adhesions. However, no commercial product is commonly used worldwide because of its insufficient efficacy, complexity, and difficulty of use. We developed a new anti-adhesion barrier using novel biomaterial (SI-449), a cross-linked chondroitin sulfate, in an easy-to-apply powder form. Our previous study using animal models showed that the anti-adhesion efficacy of SI-449 was superior to that of an existing product. In this study, the safety of SI-449 was evaluated based on the results of systemic toxicity tests in rats after intraperitoneal application and a wound healing test in laparotomized rats to mimic its clinical use in abdominal and pelvic surgeries. In the systemic toxicity test, minimal and transient hematological changes and muscular regeneration in the abdominal wall and ileum were observed and were considered to be related to systemic toxicity or local irritation due to SI-449. However, these findings were within the safety margin and not associated with serious toxicity. Other changes were considered physiological reactions to SI-449 or its degradants. In the wound healing test, SI-449 was found to have no effect on the healing of the incisional abdominal wall. In conclusion, the non-clinical safety of SI-449 was confirmed, and this novel biomaterial is expected to be used as an anti-adhesion barrier in abdominal and pelvic surgeries.

  • Open Access

    Mechanistic Insights into Cartilage Protection and Extracellular Matrix Remodeling: Transcriptome Analysis of Diclofenac Etalhyaluronate-Treated Knee Cartilage in Collagen-Induced Arthritis Rats and Cytokine-Stimulated Human Chondrocytes

    by Akihiro Kitani, Shuhei Takada, Shohei Nozaki, Kazuhiro Kojima, Kei Toyama, Takafumi Hashimoto, Jun Takeuchi, Akihiko Kawamoto, Takehito Fujita, Keiji Yoshioka

    Background: Diclofenac etalhyaluronate (DF-HA, SI-613/ONO-5704) is a conjugate of hyaluronic acid (HA) and diclofenac (DF), and its intra-articular injection is widely used for the treatment of osteoarthritis in Japan. While novel mechanisms of cartilage protection by DF-HA have been identified, a comprehensive analysis of the biological responses unique to DF-HA has not yet been conducted. Design: We used an RNA sequencing (RNA-seq) method to comprehensively analyze gene expression in the knee joint cartilage of arthritic rats and cytokine-stimulated chondrocytes. For the mechanistic analysis of DF-HA, genes that were downregulated or upregulated by DF-HA, HA, or DF were extracted. Pathway analysis was then performed on genes that specifically varied with DF-HA treatment. Results: In the cartilage of rats with collagen-induced arthritis, treatment with DF-HA, but not DF or HA, suppressed the extracellular matrix (ECM) remodeling pathway and promoted the parathyroid hormone/parathyroid hormone-related peptide receptor-mediated pathway, which regulates chondrocyte differentiation and bone/cartilage development. In cytokine-stimulated chondrocytes, DF-HA similarly suppressed the ECM remodeling pathway; specifically, gene expression changes in IGFBP4, MMP10, MMP13 , and TIMP1 were consistent with those observed in vivo . Conclusion: RNA-seq analysis of cartilage in arthritic rats and cytokine-stimulated chondrocytes provided molecular mechanistic insights, indicating that DF-HA treatment induced cartilage protection through the suppression of ECM remodeling.


  • Open Access

    Effects of Novel Cross-Linked Chondroitin Sulfate (SI-449) as a Postoperative Anti-Adhesion Barrier

    by Kei Toyama, Katsuya Takahashi, Sho Funayama, Keiji Yoshioka


  • Open Access

    Biocompatibility study of different hyaluronan products for intra-articular treatment of knee osteoarthritis

    by Keiji Yoshioka, Madoka Katayama, Takeo Nishiyama, Kohei Harada, Sawako Takeshita, Yuji Kawamata

    Background: Intra-articular (IA) injection of hyaluronic acid (HA) (IA-HA) is a well-recognized treatment option for pain associated with symptomatic knee osteoarthritis (OA). IA-HA products differ in their HA content, molecular weight, cross-linking, and source of HA. These differences are assumed to affect the biocompatibility of the IA-HA products once injected inside the knee joint. Methods: In the present study, we investigated the biocompatibility of three multiple-injection IA-HA products available in the global market. These included SUPARTZ FX™, a medium range molecular weight HA derived from rooster comb (Avian-HA); ORTHOVISC®, a high range molecular weight HA obtained through biological fermentation (Bio-HA); and SYNVISC®, a high molecular weight cross-linked hyaluronan derived from rooster comb (Avian-CL-HA). Rabbit knee joint tissues were histologically and biochemically examined after IA injection of the products. Furthermore, we compared the amounts of impurities in the IA-HA products. Results: IA injection of Avian-CL-HA into rabbit knee joints induced the aggregation of inflammatory cells, infiltration of eosinophils, and an increase in the number of cells in the synovial fluid. However, these effects were not seen in the Avian-HA and Bio-HA groups. The residual protein content and the contaminant levels of bacterial endotoxins were below the limit of quantitation in all HA products. Avian-CL-HA contained relatively a large amount of (1 → 3)-β-D-glucan, but this was below the lower limit of quantification in the other HA products. Conclusions: The present results clearly demonstrate that the biocompatibility of Avian-HA is comparable to that of Bio-HA, and they were both considered to have a favorable safety profile for the treatment of symptomatic OA of the knee. However, immunostimulatory activity was observed after injection of Avian-CL-HA: this might be a result of its unique cross-linking structure and/or the considerable amount of (1 → 3)-β-D-glucan impurity present in the formulation.


  • Open Access

    Effect of diclofenac etalhyaluronate (SI-613) on the production of high molecular weight sodium hyaluronate in human synoviocytes

    by Tomochika Kisukeda, Junichi Onaya, Keiji Yoshioka

    We have reported that a single intra-articular injection of diclofenac etalhyaluronate (SI-613) exerted a potent and long-lasting analgesic effect in experimental arthritis models. In the present study, we investigated the effect of SI-613 on the production of high molecular weight hyaluronic acid (HMW-HA) in synoviocytes from osteoarthritis (OA) patients and compared its efficacy with that of hyaluronic acid (HA). We compared the effect of SI-613, HA, and diclofenac sodium (DF-Na) on high molecular weight HA production by human synoviocytes. SI-613 and exogenous HA induced the production of high molecular weight HA in synoviocytes from OA patients, whereas DF-Na had no effect. The molecular weight of newly produced HA was about 1000 kDa in the HA-treated synoviocytes and much higher than 2400 kDa in the SI-613-treated cells. The effect of the mixture of HA and DF-Na was similar to that of HA alone in that the molecular weight of newly produced HA was around 1000 kDa. SI-613 significantly suppressed hyaluronidase 2 (HYAL2) mRNA expression and significantly enhanced hyaluronan synthase 2 (HAS2) mRNA expression. HA had no effect on the expression levels of HYAL and HAS. The present results clearly demonstrate that SI-613 induces the production of high molecular weight HA in synoviocytes from OA patients, suggesting the long-lasting analgesic and disease modifying effect of SI-613 for OA. Taken together with the anti-inflammatory and analgesic effects we recently reported for the intra-articular administration of SI-613 to experimental animal models, SI-613 holds great promise for the treatment of knee osteoarthritis.


  • Open Access

    Pharmacological effects of N-[2-[[2-[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]ethyl]hyaluronamide (diclofenac Etalhyaluronate, SI-613), a novel sodium hyaluronate derivative chemically linked with diclofenac

    by Keiji Yoshioka, Tomochika Kisukeda, Ryoji Zuinen, Yosuke Yasuda, Kenji Miyamoto

    Osteoarthritis (OA) is the most common joint disorder worldwide and one of the leading causes of disability in the elderly. We have investigated the novel sodium hyaluronate derivative chemically linked with diclofenac (DF), diclofenac etalhyaluronate (SI-613), which is a potentially safer and more effective treatment for OA knee pain. In this study, we evaluated the pharmacological effects of SI-613 in experimental arthritis models. We compared the analgesic and anti-inflammatory effects of intra-articularly administered SI-613, hyaluronic acid (HA), and of orally administered diclofenac sodium (DF-Na) in rat silver nitrate-induced arthritis model and rabbit antigen-induced arthritis model. A single intra-articular (IA) administration of SI-613 significantly suppressed pain responses in rats in a dose-dependent manner. The analgesic effects were greater than those of HA, a mixture of DF-Na and HA, or an oral once-daily administration of DF-Na. In the rabbit arthritis model, SI-613 significantly reduced knee joint swelling compared with that in the control group on day 1 after a single IA injection. This significant anti-inflammatory effect was observed until day 28. In the pharmacokinetic study, the DF concentration in the synovium after SI-613 administration reached its maximum concentration of 311.6 ng/g on day 1, and gradually declined to 10 ng/g by day 28. It fell below the lower limit of quantification on day 35. Thus, a clear correlation was found between pharmacokinetics and pharmacodynamics. These results demonstrate that SI-613 exerts its long-lasting and potent anti-inflammatory effect by sustainable release of DF in the knee joint tissues. A single IA injection of SI-613 was shown to exert analgesic and anti-inflammatory effects for 28 days in non-clinical pharmacological studies, suggesting that SI-613 will be a promising candidate in the treatment of osteoarthritis pain.